Watch APUS. Know when insiders buy.
One email the day a filing lands. Free.
APUS
Apimeds Pharmaceuticals US, Inc.
2.42
−0.09 −3.59%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.7MP/E —DIV YIELD —FCF YIELD -365.07%REV TTM —NET INCOME −$58.2MNET CASH —52W 2.42 – 38.95SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$6.3M | −$20.2M | — | -11.77 | −$5.7M | $0 | −$5.7M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$12.2M | −$35.1M | — | -2.26 | −$2.1M | $9K | −$2.1M | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$7M | −$1.2M | — | -0.08 | −$3.8M | $21K | −$3.8M | May 4 |
| Q3 2025 · Sep 30 | — | — | — | −$1.8M | −$1.8M | — | -0.14 | −$1.7M | $23K | −$1.7M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$2.7M | −$2.7M | — | -2.57 | −$3.4M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$364K | −$402K | — | -0.05 | −$20K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$276K | −$312K | — | -0.04 | −$100K | — | — | May 4 |
| Q3 2024 · Sep 30 | — | — | — | −$300K | −$333K | — | -0.04 | −$187K | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$428K | −$449K | — | -0.06 | −$184K | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$272K | −$296K | — | -0.04 | −$263K | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$11.9M | −$6M | — | -0.55 | −$8.9M | $57K | −$9M | — | — |
| FY2024 · to Dec 31 | — | — | −$1.3M | −$1.4M | — | -0.18 | −$734K | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$747K | −$778K | — | -0.17 | −$628K | — | — | — | — |
Every number comes from Apimeds Pharmaceuticals US, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.